Background: The aim of this prospective study was to investigate factors influencing long-term health-related quality of life (HRQoL) in patients treated for prostate cancer with no signs of tumor relapse.
Patients And Methods: We included epidemiological and oncological data as well as standardized questionnaires on incontinence and sexual function. Data were analyzed using standard descriptive and explorative statistics.
Results: We obtained pre-therapeutic data as well as a complete data set after 36 months for 488 patients. A total of 162 patients (33.2%) in whom we could not exclude a tumor relapse according to the guidelines of the EAU or because of incomplete data were excluded from further analysis. In a univariate analysis as expected stress incontinence, lower urinary tract symptoms (LUTS), overactive bladder (OAB), urgency, pad use, sexual activity as well as perceived pre-therapeutic HRQoL, being privately insured, and a better school education were significantly associated with post-therapeutic long-term HRQoL (p<0.05). In a multivariate analysis of covariance only dry OAB (p=0.0411) and sexual activity (p=0.0046) proved to be independent parameters with a significant impact on HRQoL after 36 months.
Conclusion: Symptoms of OAB even without urine loss after successful treatment of prostate cancer need to be addressed in clinical practice as well as in research studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00120-011-2709-1 | DOI Listing |
An Acad Bras Cienc
January 2025
Universidade Federal de Pernambuco, Departamento de Histologia e Embriologia, Av. Prof. Moraes Rego, 1235, Cidade Universitária, 50760-420 Recife, PE, Brazil.
Matrix metalloproteinases (MMP) have been identified as biomarkers for several diseases, including cancer. The increase in the expression of these enzymes has been related to greater tumor aggressiveness. MMP-26 is expressed constitutively in the endometrium and some cancer cells of epithelial origin.
View Article and Find Full Text PDFCien Saude Colet
January 2025
Instituto René Rachou, Fundação Oswaldo Cruz (Fiocruz Minas). Av. Augusto de Lima 1715, Barro Preto. 30190-002 Belo Horizonte MG Brasil.
This article aims to identify the relationship between material deprivation and mortality from breast, cervical, and prostate neoplasms in the Brazilian adult population and the relationship between ethnicity/skin color and material deprivation. This cross-sectional ecological study calculated the mean mortality rate per 100,000 inhabitants, and deaths were standardized by age and gender and redistributed per to ill-defined causes, stratified by age group and ethnicity/skin color. We applied the Negative Binomial model, containing the interaction between ethnicity/skin color and the Brazilian Deprivation Index (IBP).
View Article and Find Full Text PDFClin Cancer Res
January 2025
Stanford University, Palo Alto, CA, United States.
Purpose: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in PCa and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.
Experimental Design: Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by immunohistochemical staining.
PLoS One
January 2025
Marie Curie Research Centre, Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, United Kingdom.
To undertake a mixed-methodology implementation study to improve the well-being of men with gastrointestinal late effects following radical radiotherapy for prostate cancer. All men completed a validated screening tool for late bowel effects (ALERT-B) and the Gastrointestinal Symptom Rating Score (GSRS); men with a positive score on ALERT-B were offered management following a peer reviewed algorithm for pelvic radiation disease (PRD). Health-related quality of life (HRQoL) at baseline, 6 and 12 months; and healthcare resource usage (HRU) and patient, support-giver, staff experience and acceptability of staff training (qualitative analysis) were assessed.
View Article and Find Full Text PDFEpigenomics
January 2025
Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Background: Aggressive Variant Prostate Cancers (AVPCs) are incurable malignancies. Platinum-based chemotherapies are used for the palliative treatment of AVPC. The Polycomb Repressive Complex 2 (PRC2) promotes prostate cancer progression histone H3 Lysine 27 tri-methylation (H3K27me3).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!